CD44 and neoplasm: Indeed, treatment with T-DM1 not only depleted pre-existing CD44+/CD24−/low cells at concentrations that failed to affect the bulk of tumor cells, but also prevented the EMT-mediated induction of CSC-like properties in differentiated tumor cells [113].